GERN
Geron Corporation
There isn't enough reported data to score GERN yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
GERN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
GERN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
GERN PE Valuation
GERN has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 19x next year's earnings.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
GERN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect GERN to return to profit, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
GERN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.05 | — |
| Q3 2026 | -$0.08 | +$0.04 |
| Q2 2026 | -$0.11 | +$0.02 |
| Q1 2026 | -$0.11 | +$0.10 |
| Q4 2025 | -$0.13 | +$0.14 |
| Q3 2025 | -$0.12 | +$0.19 |
| Q2 2025 | -$0.13 | +$0.22 |
| Q1 2025 | -$0.21 | +$0.13 |
| Q4 2024 | -$0.27 | +$0.05 |
GERN is still losing money, but far less than before: $0.08 per share over the past year, against $0.39 at its worst in early 2020.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over GERN on earnings quality, reporting a profit while its opponent remains loss making.
GERN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $60.2M | +27% |
| Q2 2026 | $57.5M | +17% |
| Q1 2026 | $51.8M | +31% |
| Q3 2025 | $47.2M | +67% |
| Q2 2025 | $49M | +5460% |
| Q1 2025 | $39.6M | +12927% |
| Q3 2024 | $28.3M | +17138% |
| Q2 2024 | $882K | +2941% |
LLY has the stronger quarterly revenue trend. Revenue is up 23% for GERN versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.6% | +39 points |
| Q2 2026 | -22% | +3.7 points |
| Q1 2026 | 0.3% | +43 points |
| Q3 2025 | -29% | +70 points |
| Q2 2025 | -25% | +7836 points |
| Q1 2025 | -42% | +18423 points |
| Q3 2024 | -100% | +28932 points |
| Q2 2024 | -7861% | +171281 points |
GERN's operating margin was 9.6% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over GERN on profitability, with a higher operating margin.
GERN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $10.3M | +$23.8M |
| Q2 2026 | -$15.8M | +$11.6M |
| Q1 2026 | -$62.9M | -$14.9M |
| Q4 2025 | -$22.1M | +$21.7M |
| Q3 2025 | -$13.6M | +$45.4M |
| Q2 2025 | -$27.4M | +$26.3M |
| Q1 2025 | -$48M | +$14.9M |
| Q4 2024 | -$43.8M | -$2.8M |
GERN has burned cash in almost every quarter: −$91M over the past year, against −$133M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over GERN on cash generation, producing positive trailing cash flow while its opponent burns cash.
GERN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +7.4M shares |
| 1 year | +1.2% | +8.1M shares |
| 3 years | +24% | +130M shares |
| 5 years | +148% | +403M shares |
| Available history | +254% | +484M shares |
GERN has 674M diluted shares, up 1.2% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over GERN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
GERN Net Leverage
GERN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
GERN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.4 | Neutral |
| Stochastic | 14.7 | Oversold |
GERN's weekly RSI is 36 (neutral) and its Stochastic is 15 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
GERN PE vs Healthcare Sector
GERN has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
GERN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.11 | 11% below |
| 20 week MA | $1.30 | 24% below |
| 50 week MA | $1.38 | 28% below |
| 100 week MA | $1.55 | 36% below |
| 200 week MA | $2.35 | 58% below |
GERN is in a downtrend: it's below all five of its weekly moving averages, and 58% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over GERN on trend strength, trading above more of its moving averages.
GERN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.38 | $1.62 | +17% |
| 2021 | $1.62 | $1.37 | -15% |
| 2022 | $1.37 | $2.09 | +53% |
| 2023 | $2.09 | $2.11 | +1% |
| 2024 | $2.11 | $3.35 | +59% |
| 2025 | $3.35 | $1.37 | -59% |
| 2026 YTD | $1.37 | $0.99 | -28% |
GERN has finished higher in four of the last six years, two of them by more than 50%. It's down 28% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over GERN on returns for 2026, with the stronger performance.